Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin

Journal of Neuroscience Research

Volumn 77, Issue 1, 2004, Pages 63-81

  Paintlia, Ajaib Singh ^a   Paintlia, Manjeet Kaur ^a   Singh, Avtar Kaur ^b   Stanislaus, Romesh ^a   Gilg, Anne Genevieve ^a   Barbosa, Ernest ^a   Singh, Inderjit ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

EAE; Inflammation; Lovastatin; Microarray; Multiple sclerosis

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 4; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STATINE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC CODE; HISTOCOMPATIBILITY COMPLEX; IMMUNOBLOTTING; IMMUNOMODULATION; INFLAMMATORY CELL; LEUKOCYTE; LUMBAR SPINAL CORD; MICROANALYSIS; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TH2 CELL; UPREGULATION; VALIDATION PROCESS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; GROWTH SUBSTANCES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED LEW; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SPINAL CORD; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 3042761085     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20130     Document Type: Article

References (43)

1. Arbizu T, Alvarez-Cermeno JC, Decap G, Fernandez O, Uria DF, Garcia Merino A, Izquierdo G, Montalban X. 2000. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 102:209-217.
2. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. 2000. Non-lipid-related effects of statins. Ann Med 32:164-176.
3. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. 2003. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85:267-273.
4. Brettschneider J, Ecker D, Bitsch A, Bahner D, Bogumil T, Dressel A, Elitok E, Kitze B, Poser S, Weber F, Tumani H. 2002. The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J Neuroimmunol 133:193-197.
5. Calabresi PA. 2002. Consideration in the treatment of relapsing-remitting multiple sclerosis, Neurology 58(Suppl 4):S10-S22.
6. Calabresi PA, Fields NS, Maloni HW, Hanham A, Carlino J, Moore J, Levin MC, Dhib-Jalbut S, Tranquill LR, Austin H, McFarland HF, Racke MK. 1998. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 51:289-292.
7. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735.
8. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. 1999. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296-304.
9. Dhib-Jalbut S. 2003. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 98:245-255.
10. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. 2003. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:58-63.
11. Dimitriadou V, Pang X, Theoharides TC. 2000. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. Int J Immunopharmacol 22:673-684.
12. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, Li-Weber M. 2002. IFN-gamma represses IL-4 expression via IRF-1 and IPF-2. Immunity 17:703-712.
13. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. 2002. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944-950.
14. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. 2003. Lovastatin inhibits brain endothelial cell Pho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907.
15. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. 2003. HMG-CoA reductase inhibitor increases GTP cydohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23:176-182.
16. + T cells in a model for multiple sclerosis. J Exp Med 194:669-676.
17. Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, Thiesen HJ. 2001. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 124:1927-1938.
18. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. 2001. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class 11 expression in human vascular endothelial cells. Swiss Med Weekly 131:41-46.
19. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad, N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508.
20. Lublin FD. 1985. Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis. Springer Semin Immunopathol 8:197-208.
21. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogenesis of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
22. Markovic-Plese S, McFarland HF. 2001. Immunopathogenesis of the mulsclerosis lesion. Curr Neurol Neurosci Rep 1:257-262.
23. Maruyama S, Sumita K, Shen H, Kanoh M, Xu X, Sato M, Matsumoto M, Shinomiya H, Asano Y. 2003. Identification of IFN regulatory factor-1 binding site in IL-12 p40 gene promoter. J Immunol 170:99-1001.
24. Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H. 2002. Evaltion of the effects of 17betea-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 143:313-319.
25. Matejuk A, Hopke C, Dwyer J, Subramanian S, Jones RE, Bourdette DN, Vandenbark AA, Offner H. 2003. CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. J Neurosci Res 73:667-678.
26. Mauri C, Gray D, Mushtaq N, Londei M. 2003. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197:489-501.
27. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. 2000. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 165:5867-5873.
28. Nath N, Giri S, Prasad R, Singh AK, Singh I. 2004. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273-1286.
29. Niwa S, Totsuka T, Hayashi S. 1996. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18:669-675.
30. Pahan K, Sheikh FG, Namboodiri AM, Singh I. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671-2679.
31. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, Singh I. 2003. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 14:425-439.
32. Rice GP, Filippi M, Comi G. 2000. Cladribine and progressive MS: clinical and MR1 outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neuroloogy 54:1145-1155.
33. Singh I. 2003. Cholesterol loxyering drug shows promise for mltiple slerosis treatment. Mult Scler Quart Report 22:1-6.
34. Stanislaus R, Singh AK, Singh I. 2001. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162.
35. + MOG-specific T cells on oligomeric MHC class I molecules. Int Immunol 15:261-268.
36. Tada Y, Ho A, Matsuyama T, Mak TW. 1997. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 185:231-238.
37. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. 2002. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 91:427-433.
38. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D. 2003. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60:510-515.
39. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692.
40. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. 2001. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 69:959-962.
41. Yang XY, Wang LH, Mihalic K, Xiao W, Chen T, Li P, Wahl LM, Farrar WL. 2002. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 277:3973-3978.
42. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84.
43. Zhang J, Hutton G, Zang Y. 2002. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther 24:1998-2021.